OBJECTIVES: Combined lung and liver transplantation (Lu-LTx) is an established therapy for patients with cystic fibrosis. The initial sequence has primarily been lung first. We changed the sequence to 'liver first' in 2006. The aim of this study is to present outcomes of this procedure.
The liver-first approach for combined lung and liver transplantation INTRODUCTION Cystic fibrosis (CF) is one of the few diseases leading to failure of both the lungs and the liver but at the same time being eligible for transplantation. This multisystemic disease is characterized by epithelial electrolyte transport disorder, which leads to an elevated sweat Cl -concentration, pancreatic insufficiency and lung failure in most patients [1, 2] . Life expectancy and prolonged survival has improved in recent years and may be related to the increasing impact of liver disease management on the prognosis of CF [3, 4] .
Combined lung and liver transplantation (Lu-LTx) is an established therapy for patients with end-stage lung and liver disease with no treatment options beyond transplantation [2, 5, 6] . Arnon et al. [2] reported promising results in their analysis of the UNOS database, which reviewed the largest cohort of patients with CF undergoing Lu-LTx.
As the lung is widely considered to be more sensitive to ischaemia than the liver, the usual sequence of transplantation has been lung first. However, this sequence has disadvantages, including the frequent occurrence of primary graft dysfunction (PGD) of the lung due to coagulopathy, blood loss, transfusion and haemodynamic instability during liver transplant. Consequently, we changed the sequence at our clinic to liver first in 2006.
Ceulemans et al. reported for the first time in 2014 the results of the liver-first approach on 14 cases of Lu-LTx. In 3 cases, liver transplantation preceded lung transplantation. In these cases, the lungs were preserved by normothermic ex vivo lung perfusion [7, 8] .
In our study, we describe our short-and long-term single centre experience with patients after combined Lu-LTx according to the liver-first approach.
MATERIALS AND METHODS

Patients
We performed a retrospective single-centre study. Twenty-seven patients underwent combined Lu-LTx at our institution for different indications. Between April 1999 and October 2006, 17 patients underwent Lu-LTx beginning with the lung transplant. Among this cohort, 1 patient received a single lung transplantation followed by liver transplantation. Three patients received an en bloc heartlung transplantation followed by liver transplantation, and the remaining 12 patients received a sequential double Lu-LTx started with the lung transplant. In this group, 9 patients experienced treatment-resistant pulmonary hypertension. The underlying diseases of the other 8 patients were CF (n = 5), 1-proteinase inhibitor deficiency (n = 2) and sarcoidosis (n = 1). Because of the frequent occurrence of PGD in this cohort, we changed the sequence at our clinic to liver first in November 2006. In this group, all patients received a sequential double Lu-LTx started with the liver transplant, and all patients had CF as underlying disease.
Comparing both strategies for all patients would be very questionable due to the different underlying diseases and the accordingly different extent of the surgery.
To make both strategies as comparable as possible, patients with the same underlying disease (CF) were compared in each group (lung first n = 5 vs liver first n = 10) (Fig. 1) .
Patients, when signing the consent forms for transplantation, consented the use of their data for retrospective analysis.
Therefore, the institutional ethics committee waived the requirement to obtain reconsent for the purposes of this study. Followup was 100% and ended on 29 January 2018.
In this group, all patients received a sequential double Lu-LTx starting with the liver transplant, and all patients had CF as underlying disease. The variables PGD and chronic lung allograft dysfunction have been defined elsewhere [9] [10] [11] [12] [13] .
Clinical management
All patients were primarily listed for a combined lung and liver transplant using a specific combined organ request with the Eurotransplant. In the majority of the patients, the lung was the leading organ for allocation, carried out according to waiting time and urgency status until November 2011 and according to the lung allocation score thereafter. The respective livers were then automatically allocated from the same donor. Since November 2006, all combined Lu-LTxs were performed according to the liver-first approach, and no case by case evaluation was made. The liver retrieval was performed using the HTK preservation solution (Custodiol V R ). In the lung-first group, the lungs were harvested using low-potassium-dextran solution (Perfadex V R ). In the liver-first group, all lungs were harvested using the Celsior V R cold storage solution. All liver grafts were transplanted orthotopically without the use of any veno-venous or porto-venous bypass analogous to the procedure described by Starzl et al. [14] . The order of our anastomosis was suprahepatic vena caval, infrahepatic vena caval, portal venous and hepatic arterial. Caval clamps were released after simultaneous portal venous and hepatic arterial reperfusion of the graft and suction of the first 300 ml of reperfusional blood over a catheter through the infracaval anastomosis to prevent cardiac arrest by sluiced out preservation solution. Biliary anastomosis was accomplished in all cases with an end-to-end choledocho-choledochostomy by continuous suture.
Lung transplantations were performed as bilateral sequential transplants via bilateral sternum-sparing anterolateral thoracotomies or, in some cases, via clamshell access.
In the lung-first group, a combination of cyclosporine A (target trough level 250-300 ng/ml in the first 6 months), azathioprine and prednisolone was used only for the first patient. In the last 4 patients, azathioprine was replaced with mycophenolate mofetil, and additional induction therapy with Basiliximab was used.
Immunosuppressive therapy in the liver-first group was based on calcineurin inhibitor, mycophenolate mofetil and prednisolone. However, cyclosporine A was replaced with tacrolimus (target trough level 8-10 mg/l). Prednisolone was tapered to 10 mg/day and continued after hospital discharge. Induction therapy was not used in the 'liver-first' group.
Statistics
The data collection and analysis were performed retrospectively using SPSS 24.0 (IBM, NY, USA). The primary end point was patient survival. Categorical and continuous variables are summarized as percentages and median with interquartile range, respectively. The non-parametric Mann-Whitney test and the v 2 test or the Fisher's exact tests were used for group comparisons of continuous and categorical variables, respectively. Survival estimates were calculated by the product-limit method of Kaplan-Meier. Differences between groups were quantified using the log-rank test. P-values < _0.05 were considered statistically significant.
RESULTS
Preoperative and intraoperative patient characteristics
The perioperative data are presented in Table 1 . All patients in the lung-first group were transplanted with the status T. Prior to 2012, there were more patients with a high urgency status in the liver-first group than in the lung-first group, but the difference was not significant. The remaining patients in the liver-first group transplanted according to the lung allocation score showed a median lung allocation score of 45 (interquartile range 34-50).
At the time of transplantation, patients showed highly reduced lung function parameters with a median forced expiratory volume-%predicted of 26% (20-29%) . Patients in the lung-first group showed a median forced expiratory volume-%predicted of 29 (23-35) (P = 0.30). The majority of the patients in both groups required supplemental O 2 before transplant (80% in the lung-first group and 70% in the liver-first group).
Although none of the patients in the lung-first group were hospitalized before transplant, 4 patients (40%) were hospitalized prior to transplant in the liver-first group. Additionally, there were no cases of preoperative ventilation among the patients in both groups.
All patients in the liver-first group (100%) and in the lung-first group (100%) showed advanced cirrhosis of the liver accompanied by portal hypertension and splenomegaly. Furthermore, all patients in both groups (100%) showed oesophageal varices as a result of portal hypertension. Detailed data regarding baseline creatinine, liver functions tests and MELD score (model end stage liver disease) are reported in Table 1 .
Donor data and intraoperative results are reported in Table 2 . The majority of the recipients in both groups (80%) was transplanted via a sternum-sparing bilateral thoracotomy.
In the liver-first group, 2 (20%) patients were transplanted using extracorporeal support. One patient (10%) was transplanted using extracorporeal membrane oxygenation and 1 additional patient (10%) was transplanted using cardiopulmonary bypass (CPB). In the lung-first group, 1 case (20%) was transplanted using CPB.
The ischaemic time for the lung was significantly longer in the liver-first group (P < 0.05). Patients in the liver-first group required less blood transfusions intraoperatively than those in the lung-first group, although no statistically significant difference was revealed. However, for the overall hospital stay, the liver-first group showed a significantly lower need for packed red blood cells than patients in the lung-first group (P < 0.05) ( Table 2) .
Postoperative course
The patients in the lung-first group showed a trend towards a higher incidence of PGD Grade 2 or 3 within the first 72 h after transplant but without a statistically significant difference (Table 3) .
Ventilation times, intensive care unit (ICU) and hospital stay times were longer in the lung-first group than in the liver-first group (Table 3) . One patient in the lung-first group experienced an intrapulmonary bleeding from the left pulmonary artery. This patient additionally developed necrosis of the left donor bronchus leading to a microbiological colonization with Burkholderia cepacia, Pseudomonas aeruginosa and Enterococcus spp. and died 55 days after transplant. One patient in the liver-first group showed a portal hypertension associated with pulmonary hypertension and a decreased biventricular ejection fraction preoperatively. Consequently, this patient was transplanted using CPB and a clamshell incision. This patient had a very complicated postoperative course and developed sepsis, which required very high doses of catecholamines. The patient developed renal failure and respiratory insufficiency and required haemodialysis and a tracheostomy. A biopsy of the liver was performed, which showed extended necrotic areas. This patient experienced spontaneous liver parenchymal bleeding and died 1 month after transplant. Two (20%) additional patients in the liver-first group developed thrombosis of the liver artery, which resulted in severe graft dysfunction necessitating liver retransplant. Both patients were successfully retransplanted and discharged.
Survival and follow-up
One case of in-hospital mortality was reported in each group. In the lung-first group, 3 cases of late death were reported. The first patient developed a cytomegalovirus reactivation 9 months after transplant with severe cytomegalovirus hepatitis and cholitis and died due to multiorgan failure 12 months after transplantation. The other 2 patients developed severe pneumonia followed by multiorgan failure and died 28 and 53 months after transplantation. In the liver-first group, 1 patient died 10 months after transplant from infection due to severe pneumonia and ensuing septic multiorgan failure. During follow-up, 1 case of chronic lung allograft dysfunction was reported in the liver-first group. One additional patient (10%) in the liver-first group developed severe diffuse desquamating bronchitis with subsequent bronchial stenosis but was successfully retransplanted and discharged to the rehabilitation clinic in good clinical conditions.
The 90-day, 1-year and 5-year survival rates in the lung-first group were 80%, 60% and 20%, respectively. The patients in the liver-first group showed higher survival rates, with 90%, 80% and 80% at 90 days, 1 year and 5 years, respectively (Fig. 2) .
DISCUSSION
This study presents the largest series of the liver-first approach in patients undergoing combined Lu-LTx for CF. We describe several potentially important advantages of this approach. We also compare the results of this strategy to a small series of earlier combined transplants at our centre that were performed in the reversed sequence. The value of this comparison might be limited due to the small number of only 5 patients in the older group and due to the fact that era effects with undetected variables probably confounding the outcomes most likely are present. However, as only a small number of combined lung and liver transplants for CF are performed worldwide and more concise studies are absent in the literature, we believe these data are of interest for the field.
First, the patients in the liver-first approach required significantly less blood products during in-hospital stay. Second, in the liver-first group, occurrence of PGD 2 or 3 in the first 72 h was lower than in the lung-first group. On the other side, improved PGD may very well be related to the very low use of mechanical circulatory support in our cohort. Third, both the ICU and hospital stays were shorter in the liver-first group than in the lungfirst group.
In lung transplantation, PGD remains the leading cause of early morbidity and mortality and is a significant risk factor for chronic rejection [15] [16] [17] . Diamond et al. [17] showed in a prospective observation study of 1255 patients from 10 large US lung transplantation centres that the overall incidence of severe (Grade 3) PGD within the first 72 h post-transplantation is 30.8%. Arguably, these were the 'easier' patients, since they were lung only, rather than combined organ transplant recipients. In our study group, patients in the liver-first group had an incidence of lung PGD Grade 2 or 3, of only 10%, even though, as opposed to Diamond's study, PGD Grade 2 was also included ( Table 3) .
Above that, a trend towards favourable survival was observed in the study group (Fig. 2) . Although the 1-year survival after lung transplantation in the most recent era (2009-2014) is approximately 84% according to the International Society for Heart and Lung Transplantation (ISHLT) registry, our liver-first cohort demonstrates 1-year survival of 80%, which is well in the range of the expected overall survival after lung transplantation [18] . In 1995, Couetil et al. [19] published one of the first and largest single-centre studies on combined Lu-LTx for CF. Ten patients underwent one of the following procedures: heart-lung-liver transplantation (n = 5), en bloc double lung-liver transplantation (n = 1), sequential double lung-liver transplantation (n = 3) and bilateral lobar lung transplantation from a split left lung and reduced liver transplantation (n = 1) with survival rates of 70% after 1 year and 3 year. In that study, CPB was used in all patients, most likely because it was standard practice at the time. The intrathoracic procedure was completed before abdominal surgery was initiated. Pulmonary infection was the most common cause of early post-transplant morbidity in that cohort [19, 20] .
Similar results were reported by Barshes et al. [5] in their study describing the outcome of 11 patients receiving a combined LuLTx for CF with 1-year and 5-year survival rates of 79% and 63%, respectively. The lung transplantation was performed on CPB, and the chest was left open for the remainder of the abdominal operation [5] . Arnon et al. [2] analysed the UNOS database and published the largest case series in the USA with a total of 15 patients undergoing a combined Lu-LTx (all using the lung-first approach) for CF with 1-year and 5-year survival rates of 80% and 80%.
In 2008, we published one of the first European reports on 13 consecutive cases of combined Lu-LTx for different indications [21] . Eleven patients received a bilateral Lu-LTx, 1 patient received a single lung followed by a liver transplantation and 1 patient received an en bloc heart-lung and liver transplantation. In 5 patients, CPB was used. The overall survival rates at 1, 3 and 5 years were 69%, 62% and 49%, respectively [21] . At this time, the preferred sequence of transplantation was primarily lung first due to the anticipated sensitivity of the lungs to ischaemic time, which was believed to be greater than that of the liver. However, because of a number of drawbacks associated with this transplantation sequence, we changed our approach to liver first.
It should be mentioned that among the cohort of our study published in 2008, 5 patients had CF as an underlying disease. These patients are identical with the lung-first group in this current work.
The liver-first principle was first described by Ceulemans et al. [7, 8] to correct the coagulation status, which may reduce the need for transfusions during the ensuing lung transplantation, potentially preventing reperfusion oedema (and thus PGD) in the new lungs. An additional hypothetical benefit of the liver-first principle is to reduce the cold ischaemic time of the liver, which may reduce the rates of biliary strictures after transplant [22] . The lungs were normothermically preserved using ex vivo lung perfusion in anticipation of the extended preservation time. In the study by Ceulemans, 14 consecutive cases of combined liver/ thoracic transplantation were performed between 2000 and 2015 [8] . Thoracic organs were transplanted first except in 3 cases where the liver transplantation preceded the lung transplantation. In the first 2 cases, the transplantation of both organs were performed without any difficulties. Because of the poor oxygen delivery during the liver transplant in the third case, Ceulemans suggested that it might be preferable to perform the lung transplant first. This case triggered their discussion on the 'sickestorgan first' principle. The described follow-up of this cohort is relatively short; however, the results reported appear promising. In our study cohort, no case of ex vivo lung perfusion was performed during the liver transplantation; however, the application of this procedure could well be considered.
Hepatic artery thrombosis is a severe vascular complication after liver transplantation. The reported incidence ranges from 2% to 15% [23] [24] [25] . Twenty percent of the patients in the liverfirst group developed early hepatic artery thrombosis and needed liver retransplant. The rate of hepatic artery thrombosis in our cohort is quite high compared to the published data; however, in contrast to the published data, complex combination transplantations were performed in our study cohort. On the other side, this percentage of patients should be treated with caution given the extremely low number of cases.
In the long run, however, death due to chronic rejections of the lungs is absent in our liver-first group. This may well be triggered by the 'liver effect', cited by authors investigating the inherent tolerogenic potential of different solid organs transplanted [26, 27] . Given the excellent long-term survival of liver recipients and the low incidence of chronic rejections of the liver, this organ has always been deemed a 'pro-tolerogeneic' organ. This liver effect is believed to maintain a bystander effect on other cotransplanted organs from the same donor. However, the absence of chronic rejections of the lungs in our liver-first group may also mean more than that. The prolonged ischaemic times for the lungs seem not to have a detrimental effect on graft survival. If this is per se true or if a potential detrimental effect is simply outweighed by the tolerogeneic liver effect remains unresolved and will need additional future study. Furthermore, the protective effect of the liver to the kidney has been reported in the field of combined kidney and liver transplantation. It has been described that circulating alloantibodies may be neutralized by Class I HLA antigens produced by the transplanted liver. HLA matching of the second graft with the previous one (kidney after liver) was associated with less incidence of acute rejection of the kidney and improved outcome overall [28] .
Limitations
We performed a retrospective single-centre study with a very low number of cases. Both groups were transplanted in different eras, using deferent preservation solutions and immunosuppressive Figure 2 : Because of the small number of patients in our study, overall survival was not statistically different among patients in the liver-first group and in the lung-first group.
therapies. Thus, an era effect with learning curve, presumably improved operative and ICU care, may be assumed and have to be considered. Furthermore, the younger age of the donors in the liver-first group may well be instrumental in success.
CONCLUSIONS
The liver-first sequence displayed a trend towards less transfusion requirements, less PGD, shorter ICU and hospital stays and, finally, improved survival. These outcomes were realized without detrimental effects of the prolonged lung ischaemic time, especially without increased rates of chronic rejection. Therefore, the liverfirst approach to combined Lu-LTx is a worthwhile strategy and will be continued by our programme.
